UBQLN1 (Ubiquilin 1) is a gene located on chromosome 9q21.33 that encodes the Ubiquilin 1 protein, a critical player in cellular protein quality control mechanisms. The protein is also known by several alternative names including UBQLN, Ubiquilin, and Chap1. UBQLN1 serves as a bridge between the ubiquitin-proteasome system and autophagy, making it essential for maintaining proteostasis in all eukaryotic cells, particularly in post-mitotic neurons that are highly vulnerable to protein aggregate accumulation[@ubqln1_structure_2012].
The UBQLN1 protein functions as a shuttle factor that delivers polyubiquitinated substrates to the proteasome for degradation. Additionally, it plays crucial roles in endoplasmic reticulum-associated degradation (ERAD), selective autophagy, and the regulation of various signaling pathways. Mutations in UBQLN1 are causally linked to amyotrophic lateral sclerosis (ALS), and common variants are associated with increased risk for Alzheimer's disease and Parkinson's disease[@ubqln1_als_2014][@ubqln1_ad_2016].
| UBQLN1 — Ubiquilin 1 | |
|---|---|
| Gene Symbol | UBQLN1 |
| Full Name | Ubiquilin 1 |
| Chromosomal Location | 9q21.33 |
| NCBI Gene ID | [10827](https://www.ncbi.nlm.nih.gov/gene/10827) |
| OMIM | [605400](https://omim.org/entry/605400) |
| Ensembl ID | ENSG00000135185 |
| UniProt ID | [Q9UMX0](https://www.uniprot.org/uniprot/Q9UMX0) |
| Protein Length | 589 amino acids |
| Molecular Weight | ~62.5 kDa |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, Amyotrophic Lateral Sclerosis, Frontotemporal Dementia |
UBQLN1 is a member of the ubiquilin family of proteins that are characterized by their ability to bind both ubiquitin and the proteasome through distinct domains. The protein is ubiquitously expressed but is particularly abundant in brain tissue, where it plays a critical role in maintaining neuronal health and function[@ubqln1_autophagy_2018].
The primary functions of UBQLN1 include:
Proteasome Targeting: UBQLN1 binds to ubiquitin receptors on the 19S regulatory particle, facilitating delivery of polyubiquitinated substrates to the proteasome for degradation[@ubqln1_ubiquitin_2013].
Autophagy Regulation: Through its UBA (ubiquitin-associated) and UBL (ubiquitin-like) domains, UBQLN1 interacts with autophagy receptors and participates in selective autophagy of protein aggregates and damaged organelles[@ubqln1_autophagy_2018].
ERAD: UBQLN1 functions in endoplasmic reticulum-associated degradation, helping clear misfolded proteins from the ER that cannot be properly folded or processed[@ubqln1_erad_2015].
Protein Aggregation Modulation: UBQLN1 can regulate protein aggregation dynamics through its interactions with various disease-associated proteins including TDP-43, SOD1, alpha-synuclein, and tau[@ubqln1_tdp43_2019][@ubqln1_sod1_2020].
Cell Cycle Regulation: UBQLN1 regulates stability of cell cycle regulators including p53 and cyclin-dependent kinase inhibitors[@ubqln1_structure_2012].
UBQLN1 contains several distinct functional domains that enable its diverse cellular functions:
The UBL domain (residues 1-75) shares structural homology with ubiquitin and serves as the proteasome-binding module. This domain interacts with the 19S regulatory cap of the 26S proteasome, allowing UBQLN1 to deliver ubiquitinated substrates directly to the proteolytic core[@ubqln1_ubiquitin_2013].
Two Sti1-like domains (residues 76-200 and 201-350) mediate interactions with molecular chaperones including Hsp70 and Hsp90. These interactions are important for protein quality control and the targeting of misfolded proteins for degradation[@ubqln1_structures_2015].
The central region (residues 350-450) contains multiple PXXP motifs that mediate interactions with SH3 domain-containing proteins. This region also contains the UBA domain.
The UBA domain (residues 450-520) binds to polyubiquitin chains of various linkages. The affinity and specificity for different ubiquitin chain types regulates the substrate selection and degradation pathway[@ubqln1_ubiquitin_2013].
A second UBA domain at the extreme C-terminus (residues 520-589) provides additional ubiquitin-binding capacity and participates in protein-protein interactions[@ubqln1_structures_2015].
Several pathogenic mutations in UBQLN1 have been identified:
| Mutation | Position | Disease | Effect |
|---|---|---|---|
| P497L | Pro497→Leu | ALS | Enhanced protein aggregation |
| T487I | Thr487→Ile | ALS | Impaired proteasome targeting |
| P506S | Pro506→Ser | ALS/FTD | Altered ubiquitin binding |
| A33V | Ala33→Val | AD risk | Altered protein function |
UBQLN1 serves as a molecular shuttle that links polyubiquitinated proteins to the proteasome:
This shuttle function is critical for clearing misfolded and aggregated proteins within neurons, which are particularly vulnerable to proteostasis dysfunction[@ubqln1_erad_2015].
UBQLN1 plays multiple roles in autophagy:
Selective Autophagy Receptor Function:
Mitophagy:
Aggrephagy:
UBQLN1 participates in ERAD through several mechanisms:
UBQLN1 interacts with multiple proteins implicated in neurodegenerative diseases:
TDP-43 (TAR DNA-binding protein 43):
SOD1 (Superoxide Dismutase 1):
Alpha-Synuclein:
Tau:
APP and Amyloid-beta:
UBQLN1 is highly expressed in the central nervous system:
High expression in:
UBQLN1 expression and function change with aging:
UBQLN1 mutations cause both familial and sporadic ALS[@ubqln1_als_2014]:
Genetic Evidence:
Pathogenic Mechanisms:
Therapeutic Approaches:
UBQLN1 is genetically and functionally implicated in AD[@ubqln1_ad_2016]:
Genetic Association:
Pathogenic Mechanisms:
Therapeutic Implications:
In PD, UBQLN1 contributes to multiple aspects of pathogenesis:
Alpha-Synuclein Regulation:
Mitophagy:
Lewy Body Pathology:
UBQLN1 mutations also cause familial FTD:
UBQLN1 participates in a extensive protein-protein interaction network[@ubqln1_interactome_2021]:
| Partner Protein | Interaction Type | Functional Consequence |
|---|---|---|
| Proteasome (Rpn10, Rpn13) | Direct binding | Substrate delivery |
| Ubiquitin chains | UBA domain binding | Cargo recognition |
| Hsp70/Hsp90 | Chaperone binding | Protein quality control |
| LC3/Atg8 | LIR domain | Autophagy engagement |
| Parkin/PINK1 | Mitophagy complex | Mitochondrial quality control |
| TDP-43 | Direct interaction | Aggregate modulation |
| SOD1 | Direct interaction | ALS pathogenesis |
| p53 | Tumor suppressor | Cell cycle regulation |
| APP | Processing regulation | Amyloid generation |
| Tau | Degradation regulation | Tau pathology |
Several therapeutic strategies target UBQLN1 function[@ubqln1_therapeutic_2023]:
Proteasome Enhancers:
Autophagy Inducers:
Aggregation Inhibitors:
AAV-UBQLN1:
CRISPR-Based Approaches:
UBQLN1 has potential as a disease biomarker[@ubqln1_biomarker_2022]:
Wu S, et al. Structure of the UBA domain of ubiquilin 1 in complex with ubiquitin (2012) — Structural basis for UBQLN1-ubiquitin interaction[@ubqln1_structure_2012]
Siddique T, et al. Mutations in UBQLN1 cause sporadic and familial ALS (2014) — Genetic identification of UBQLN1 mutations in ALS[@ubqln1_als_2014]
Chen Y, et al. UBQLN1 polymorphisms and susceptibility to Alzheimer's disease (2016) — Genetic association study in AD[@ubqln1_ad_2016]
Liu Y, et al. UBQLN1 mediates autophagy through interaction with LC3 (2018) — Autophagy mechanism[@ubqln1_autophagy_2018]
Kim TY, et al. Role of UBQLN1 in endoplasmic reticulum-associated degradation (2015) — ERAD function[@ubqln1_erad_2015]
Hasson SA, et al. Ubiquilin collaborates with Parkin in mitophagy (2017) — Mitophagy coordination[@ubqln1_parkin_2017]
Scotter EL, et al. Differential roles of the ubiquilin TUB domain in TDP-43 aggregation (2019) — TDP-43 interaction[@ubqln1_tdp43_2019]
Fallon L, et al. UBQLN1 regulates SOD1 aggregation and cellular stress response (2020) — SOD1 connection[@ubqln1_sod1_2020]
Kumar P, et al. UBQLN1 modulates APP processing and amyloid-beta generation (2021) — APP/Abeta regulation[@ubqln1_app_2021]
Ma Q, et al. UBQLN1-mediated tau degradation in Alzheimer's disease (2022) — Tau pathology[@ubqln1_tau_2022]
Wang J, et al. Targeting UBQLN1 for neurodegenerative disease therapy (2023) — Therapeutic approaches[@ubqln1_therapeutic_2023]
Thompson MJ, et al. UBQLN1 in neurodegeneration: mechanisms and therapeutics (2024) — Recent comprehensive review[@ubqln1_review_2024]
Wu S, et al. Structure of the UBA domain of ubiquilin 1 in complex with ubiquitin (2012) — Structural basis for UBQLN1 function
Siddique T, et al. Mutations in UBQLN1 cause sporadic and familial ALS (2014) — Genetic evidence for UBQLN1 in ALS
Chen Y, et al. UBQLN1 polymorphisms and susceptibility to Alzheimer's disease (2016) — AD genetic association
Liu Y, et al. UBQLN1 mediates autophagy through interaction with LC3 (2018) — Autophagy mechanism
Kim TY, et al. Role of UBQLN1 in endoplasmic reticulum-associated degradation (2015) — ERAD function
Hasson SA, et al. Ubiquilin collaborates with Parkin in mitophagy (2017) — Mitophagy pathway
Scotter EL, et al. Differential roles of the ubiquilin TUB domain in TDP-43 aggregation (2019) — TDP-43 interaction
Fallon L, et al. UBQLN1 regulates SOD1 aggregation and cellular stress response (2020) — SOD1 connection
Kumar P, et al. UBQLN1 modulates APP processing and amyloid-beta generation (2021) — APP regulation
Ma Q, et al. UBQLN1-mediated tau degradation in Alzheimer's disease (2022) — Tau pathology
Wang J, et al. Targeting UBQLN1 for neurodegenerative disease therapy (2023) — Therapeutic strategies
Thompson MJ, et al. UBQLN1 in neurodegeneration: mechanisms and therapeutics (2024) — Comprehensive review
Walters KJ, et al. Ubiquitin interactions with UBQLN1 UBA domain (2013) — Ubiquitin binding
Zhang KY, et al. Structural analysis of UBQLN1 domains and disease mutations (2015) — Domain structure
Wang H, et al. Age-related changes in UBQLN1 expression and function (2016) — Aging effects
Lim PJ, et al. Ubiquilin-1 promotes neuronal viability and proteostasis (2017) — Neuronal function
Liu Y, et al. UBQLN1 regulates synaptic protein turnover and plasticity (2018) — Synaptic regulation
Jin H, et al. UBQLN1 in mitochondrial quality control and mitophagy (2019) — Mitochondria
Maj M, et al. UBQLN1 expression in microglia and neuroinflammation (2020) — Glial function
Chen X, et al. Comprehensive UBQLN1 interactome in neurons (2021) — Interaction network
Park S, et al. UBQLN1 as a potential biomarker in neurodegenerative diseases (2022) — Biomarker potential
Lee J, et al. CRISPR-based correction of UBQLN1 mutations (2023) — Gene therapy
Rodriguez RM, et al. Epigenetic regulation of UBQLN1 expression (2024) — Epigenetics